Nucleus accumbens-1 (Nac1 or NAC-1) belongs to the BTB/POZ (Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad complex) transcription factor family and is a novel protein that potentially participates in self-renewal and pluripotency in embryonic stem cells. In human cancer, NAC-1 is upregulated in several types of neoplasms, but particularly in recurrent chemoresistant ovarian carcinomas, suggesting a biological role for NAC-1 in the development of drug resistance in ovarian cancer. We have assessed this possibility and shown a correlation between NAC-1 expression and ex vivo paclitaxel resistance in ovarian serous carcinoma tissues and cell lines. We found that expression of Gadd45-c-interacting protein 1 (Gadd45gip1), a downstream target negatively regulated by NAC-1, was reduced in paclitaxel-resistant cells. Ectopic expression of NAC-1 or knockdown of Gadd45gip1 conferred paclitaxel resistance, whereas NAC-1 knockdown or ectopic expression of Gadd45gip1 increased paclitaxel sensitivity. Furthermore, silencing NAC-1 expression or disrupting NAC-1 homodimerization by a dominant negative NAC-1 protein that contained only the BTB/POZ domain induced the expression of Gadd45c, which interacted with Gadd45gip1. Reducing Gadd45c expression by small hairpin RNAs partially enhanced paclitaxel resistance. Thus, this study provides new evidence that NAC-1 upregulation and homodimerization contribute to tumor recurrence by equipping ovarian cancer cells with the paclitaxel-resistant phenotype through negative regulation of the Gadd45 pathway.
Introduction
Ovarian cancer represents the most lethal gynecological malignant disease in the United States with an estimated 22 430 new cases and 15 280 deaths in 2007 (Jemal et al., 2007) . Unlike other histological types of ovarian epithelial tumors, high-grade serous carcinoma is the most aggressive and most rapidly growing neoplasm, and has a 5-year survival rate below 30%. Patients with high-grade serous carcinomas always present their diseases at the advanced stages. These patients routinely receive cytoreduction surgery followed by a combined carboplatin/paclitaxel chemotherapy regimen. Despite initial responsiveness to the chemotherapeutic drugs, most patients eventually develop chemoresistant tumors and succumb to their diseases. Therefore, treatment failure is often attributed to primary or acquired resistance to chemotherapeutic agents, which remains a clinically formidable problem in managing most cancer patients. Understanding chemoresistance at the molecular level should illuminate fundamental properties of drug resistance and provide new therapeutic targets to treat advanced neoplastic diseases.
In an effort to elucidate the molecular etiology of drug resistance, we have earlier identified and characterized the nucleus accumbens-1 (Nac1 or NAC-1) as one of the candidate chemoresistance genes in ovarian cancer (Nakayama et al., 2006a, b) . NAC-1 is a nuclear protein belonging to the BTB/POZ (Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad complex) domain family. NAC-1 was originally identified and cloned as a novel transcript from the NAC, a unique forebrain structure involved in reward motivation and addictive behaviors (Koob, 1996; Cha et al., 1997; Kalivas et al., 1999; Mackler et al., 2000) , and it was later shown to be involved in the acute behavioral and neurochemical responses to psychomotor stimulants (Mackler et al., 2008) . Recently, NAC-1 has been found to be one of the factors associated with pluripotency in embryonic stem (ES) cells. NAC-1 transcriptionally regulates gene expression of other pluripotency factors, including Nanog, Oct4, Sox2, Klf4, Sall1 and Sall4, and participates in constituting the protein interaction and transcriptional regulatory networks that are critical to establish and/or maintain ES cell pluripotency Kim et al., 2008; Muller et al., 2008) . In human cancer, NAC-1 is upregulated in several neoplasms, including ovarian high-grade serous carcinoma, pancreatic carcinoma, colorectal carcinoma, breast carcinoma, renal cell carcinoma, hepatocellular carci-noma and cervical cancer (Nakayama et al., 2006a, b; Yeasmin et al., 2008) . In ovarian high-grade serous carcinomas, the levels of NAC-1 expression were significantly higher in recurrent post-chemotherapy samples than in primary earlier untreated tumors (Nakayama et al., 2006a, b; Davidson et al., 2007) . Furthermore, intense NAC-1 immunoreactivity in primary ovarian serous carcinomas was associated with early recurrence, suggesting that NAC-1 is potentially involved in the pathogenesis of drug resistance.
At the molecular level, NAC-1 proteins form homodimers through the BTB/POZ domain, and this process is essential for tumor-cell growth and survival in tumors with NAC-1 overexpression (Nakayama et al., 2006a, b) . NAC-1 has been shown to interact with nuclear proteins, including CoRest and histone deacetylases, HDAC3 and HDAC4, in which the binding with deacetylases is mediated by a unique BEN domain on NAC-1 protein (Korutla et al., 2005 (Korutla et al., , 2007 Abhiman et al., 2008) . Ectopic expression of fulllength NAC-1 proteins is sufficient to enhance tumorigenecity of ovarian surface epithelial cells and of NIH3T3 cells in athymic nu/nu mice. We have previously identified growth arrest and DNA-damageinducible Gadd45-g interacting protein (Gadd45gip1) as one of the genes negatively regulated by NAC-1, and have shown that NAC-1 contributes to tumor growth and survival, at least in part, by inhibiting Gadd45gip1 expression (Nakayama et al., 2007) . The above findings strongly suggest that NAC-1 is a tumor recurrenceassociated gene in high-grade ovarian serous carcinomas. In this study, by correlating NAC-1 expression and drug-resistance status, we determined that NAC-1 causally contributes to chemoresistance for paclitaxel and carboplatin and showed that the Gadd45 pathway is involved in NAC-1-mediated chemoresistance in cancer cells.
Results
Correlation of NAC-1 expression and paclitaxel resistance in ovarian carcinoma Three ovarian cancer cell lines, SKOV3, OVCAR3 and A2780, were used to generate paclitaxel-resistant cells. Dose-dependent growth inhibition effects by paclitaxel are shown in Figure 1a . The IC50s of paclitaxel at 96 h were o0.1 nM in all the three parental naive cell lines, but were more than 5000 nM in all the three paclitaxelresistant cell lines. Quantitative real-time reverse transcription PCR was used to determine NAC-1 transcript levels in the resistant and parental naive cells from each cell line. As shown in Figure 1b , NAC-1 mRNA was highly expressed in paclitaxel-resistant cells as compared with parental cells in all three different cell lines (Student's t test P-value o0.001). To extrapolate the above findings to clinical specimens, we performed immunohistochemistry using an anti-NAC-1 antibody on a total of 113 high-grade ovarian serous carcinomas, for which the ex vivo drug-response status was available. We showed a correlation between the intensity of NAC-1 immunoreactivity and an extreme paclitaxel-resistance status (P ¼ 0.05) ( Table 1 ). In contrast, there was no significant correlation (P ¼ 0.43) between carboplatin resistance and NAC-1 immunointensity. Therefore, we focused on the mechanism underlying how NAC-1 participates in paclitaxel resistance in ovarian cancer.
NAC-1 overexpression confers paclitaxel resistance
To assess whether or not NAC-1 expression causally contributes to paclitaxel resistance, we used both Figure 2a , three independent NAC-1-expressing clones were more resistant to paclitaxel-induced growth suppression than a control clone transfected with the vector alone. The IC50s of paclitaxel at 96 h were 785, 755 and 692 nM in NAC-1-expressing clones in contrast to 59 nM in the control clone (Figure 2a, upper panel) . Growth curve analysis showed an increase in proliferation rate of NAC-1-expressing clones as compared with the control cells, in the presence of paclitaxel (Figure 2a , lower panel). Next, we applied small hairpin RNAs (shRNAs) targeting NAC-1 in SKOV3 cells that expressed high levels of NAC-1 protein. The efficiency of shRNAs in reducing NAC-1 protein expression is shown in Figure 2b . Similar to our previous finding (Nakayama et al., 2006a, b) , NAC-1 knockdown resulted in growth suppression in parental SKOV3 cells, but not in paclitaxel-resistant SKOV3 cells (Supplementary Figure 1A) . The sensitivity to paclitaxel was then determined in control and NAC-1 shRNA-treated paclitaxel-resistant SKOV3 cells. We found that NAC-1 knockdown increased paclitaxel sensitivity, especially at higher concentrations of paclitaxel. The IC50s of paclitaxel at 96 h were 2839 and 3275 nM in shNAC1-1 and shNAC1-3-treated groups, resepectively, and 12 087 nM in the control shRNA-treated cells ( Figure 2c ).
Gadd45gip1 is associated with paclitaxel resistance in ovarian cancer cells
Nucleus accumbens-1 (NAC-1) is thought to be a transcription regulator and has been shown to negatively control Gadd45gip1 expression (Nakayama et al., 2007) . Thus, it is likely that Gadd45gip1 may contribute, at least in part, to the paclitaxel-resistance phenotype.
To test this hypothesis, we first compared the mRNA levels of Gadd45gip1 between paclitaxel-resistant and parental naive ovarian cancer cell lines, and found that the Gadd45gip1 transcript level was significantly reduced in paclitaxel-resistant cells as compared with their naive counterparts in all three cell lines ( Figure 3a) . Next, we knocked down Gadd45gip1 expression using shRNA to determine whether reducing Gadd45gip1 level enhanced paclitaxel resistance. Figure 3b shows that the mRNA levels of Gadd45gip1 were significantly reduced 48 h after treating paclitaxel-resistant SKOV3 cells with two Gadd45gip1 shRNAs. Growth curve analysis showed that Gadd45gip1 shRNA transfection did not significantly alter the proliferation rate in either paclitaxel-resistant or control SKOV3 cells (Supplementary Figure 1B ). However, Gadd45gip1 shRNAs decreased paclitaxel sensitivity in paclitaxel-resistant SKOV3 cells. The IC50s of paclitaxel (measured after 96 h) were 3108 nM in the Gadd45gip1-knockdown paclitaxel-resistant cells, and 1805 nM in the control paclitaxel-resistant cells ( Figure 3c ). Likewise, Gadd45-gip1 shRNAs also decreased paclitaxel sensitivity in naive SKOV3 cells (data not shown). Furthermore, we NAC-1 in paclitaxel resistance N Jinawath et al overexpressed Gadd45gip1 in paclitaxel-resistant SKOV3 cells using the retrovirus delivery system. Western blot analysis showed Gadd45gip1 protein expression in Gadd45gip1 virus-transduced cells, but not in pWZL (vector control) virus-transduced cells (Figure 4a ). At 48 h after viral infection, cells were incubated with serial concentrations of paclitaxel and the IC50 was measured four days later. We found that ectopic Gadd45gip1 expression significantly increased the paclitaxel sensitivity in paclitaxel-resistant SKOV3 cells. The IC50 s of paclitaxel were 2320 nM in Gadd45-gip1-overexpressed paclitaxel-resistant cells and 35 512 nM in the vector control paclitaxel-resistant cells (Figure 4b ).
The role of Gadd45g in the development of paclitaxel resistance As Gadd45gip1 interacts with all three Gadd45 isoforms, including Gadd45a, Gadd45b and Gadd45g, we determined whether Gadd45 protein(s) was also regulated by NAC-1. For these experiments we used SKOV3 cells, which were engineered with an N130 Tet-off inducible system. N130 is a truncated NAC-1 protein (1-130 amino acids) containing only the BTB/POZ domain. It has been shown that N130 proteins competitively interact with full-length NAC-1 molecules, preventing them from forming NAC-1 homodimers, and induce cell death (Nakayama et al., 2006a, b) . We also generated N130 mut by random mutagenesis, and the sequence of N130 mut comparing with the N130 wt is shown in Supplementary Figure 2A . We established both N130 wt -and N130 mut -inducible SKOV3 cell lines using the Tet-off system. We found that unlike N130 wt protein, N130 mut protein was not colocalized with endogenous NAC-1 ( Figure 5 ) and did not exert a growth inhibitory effect (Supplementary Figure 2B) . Next, we assessed gene expression in three Gadd45 isoforms after N130 wt or N130 mut induction on the basis of the assumption that NAC-1 signaling could also affect the expression levels of Gadd45gip1 binding partners for an efficient regulation of the function in the Gadd45/Gadd45gip1 complex. As shown in Figure 6a , Gadd45g expression increased 24 h after N130 induction. We also found that Gadd45a mRNA levels NAC-1 in paclitaxel resistance N Jinawath et al increased in the first 24 h then decreased afterwards, whereas Gadd45b expression did not show any significant change after N130 induction (data not shown).
In contrast, induction of N130 mut did not have any effect on the expression of all the Gadd45 isoforms. The effect of N130 mut on Gadd45g is shown in Figure 6a . Next, we transfected SKOV3 and HeLa cells with NAC-1 shRNA and observed that the copy number of Gadd45g transcript increased after NAC-1 knockdown (Figure 6b) . In SKOV3 cells, a smaller reduction in NAC-1 RNA caused a mild (but significant) increase in GADD45-g expression, whereas in HeLa cells, a larger reduction in NAC-1 led to a pronounced increase in GADD45-g expression. Thus, the findings based on both NAC-1 knockdown and N130 mut approaches indicated that NAC-1 expression and homodimerization were essential to suppress Gadd45g expression. We also determined whether Gadd45g was causally involved in developing paclitaxel resistance on the basis of IC50 curve analysis after gene knockdown. We found that both paclitaxel-resistant and naive cells in the Gadd45g knockdown group became more resistant to paclitaxelinduced growth suppression than the control-treated group. The IC50s of paclitaxel at 96 h were B12 000 nM in Gadd45g-knockdown paclitaxel-resistant cells and B6000 nM in the control paclitaxel-resistant cells (Supplementary Figure 3) .
Discussion
Most ovarian cancer patients are initially responsive to carboplatin-paclitaxel combination chemotherapy, but the majority of them eventually develop recurrent chemoresistant tumors, which account for the high mortality in ovarian cancer patients. In an earlier report, we showed that NAC-1 upregulation in ovarian serous carcinomas was significantly associated with early tumor recurrence after cytoreduction therapy and paclitaxelcarboplatin combined chemotherapy (Nakayama et al., 2006a, b) . In this study, we determined the biological roles of NAC-1 in developing drug resistance in ovarian cancer. Our results provide evidence that NAC-1 upregulation contributes to tumor recurrence by equipping ovarian cancer cells with the paclitaxel-resistant phenotype through negative regulation of the Gadd45 pathway.
The results of this study have implications regarding the pathogenesis of ovarian cancer. Our finding that NAC-1 participates in the development of paclitaxel resistance in ovarian cancer is consistent with a recent report , and further supports the view that NAC-1 is a paclitaxel-resistance-associated gene. It has been shown that one of the stemness properties of cancer-initiating (stem-like) cells is the development of resistance to chemotherapeutic agents. For example, ovarian cancer-initiating cells are highly resistant to cisplatin or paclitaxel treatment (Zhang et al., 2008) . Acquisition of the stem cell-like phenotype is often associated with upregulation of several ES cell markers, including Notch-1, Nanog, nestin and Oct-4, as compared with parental tumor cells. Recently, new evidence has shown a role of NAC-1 as an important transcriptional regulator in maintaining ES cell pluripotency. An extended regulatory network necessary for preserving the pluripotent state of ES cells has been recently reported Kim et al., 2008) , and NAC-1 was shown to be a primary Nanoginteracting protein that is part of the protein regulatory complex responsible for maintaining pluripotency . NAC-1 protein complex has been shown to transcriptionally regulate approximately 800 genes in ES cells (Kim et al., 2008) . Interestingly, NAC-1 itself was determined to regulate transcription of the transcription factors, Nanog, Oct4 and Sox2, which seemed to be essential for development and maintenance of the pluripotent state of ES cells (Boyer et al., 2005) . Given that NAC-1 likely participates in transcriptional regulation of these genes in the maintenance of cell pluripotency, it is plausible that NAC-1 contributes to drug resistance by enhancing stem-cell-like features of ovarian cancer cells.
Demonstration of NAC-1-mediated drug resistance by the Gadd45 pathway is of great interest, because the Gadd45 pathway plays a major role in cell cycle arrest and apoptosis under cellular stress, such as in the presence of chemotherapeutic agents (Zerbini and Libermann, 2005a, b) . In this report and our earlier study, we have shown that NAC-1 proteins negatively regulate the expression of Gadd45gip1 (Crif1) (Nakayama et al., 2007) and Gadd45g. Gadd45gip1 (Crif1) has been shown to interact with all Gadd45 isoforms, and importantly, the interaction between Gadd45gip1 and Gadd45 members enhances the functions of the Gadd45 NAC-1 in paclitaxel resistance N Jinawath et al complex (Chung et al., 2003) . Expression of Gadd45a and Gadd45g activates MEKK4/MTK1, which then activates MKK4. MKK4 activation, in turn, leads to p38/JNK (janus kinase) activation by phosphorylation, resulting in apoptosis/growth inhibition (Verheij et al., 1996; De Smaele et al., 2001; Zerbini and Libermann, 2005a, b) . It has also been shown that Gadd45a and Gadd45g are down-regulated as a consequence of NFkB pathway activation through upregulation of c-myc. Suppression of both Gadd45 members is essential for cancer cells to survive (De Smaele et al., 2001; Tang et al., 2001; Zerbini et al., 2004) . Thus, survival signals from at least two different oncogenic pathways, that is, NAC-1 and NF-kB, converge on one molecular 'hub', which is Gadd45/Gadd45gip1. Inhibition of NF-kB has been shown to sensitize ovarian cancer cells to cisplatin and paclitaxel-induced apoptosis (Mabuchi et al., 2004; Liu et al., 2006) . Thus, turning off the Gadd45 pathway seems to be critical for cancer cell survival and to facilitate tumor growth under cellular stress. In addition to the established NF-kB-Gadd45 molecular circuit, downregulation of Gadd45gip1 by NAC-1 overexpression represents another molecular switch to suppress Gadd45 death signals. It is likely that in the evolution of cancer cell species, tumor cells acquire multiple strategies to inactivate Gadd45 cell suppressor signaling. In fact, overexpression of NF-kB (Mabuchi et al., 2004; Liu et al., 2006) , gene amplification and transcriptional upregulation of c-myc (Baker et al., 1990; Abeysinghe et al., 1999; Dimova et al., 2006) and Gadd45 promoter methylation (Qiu et al., 2004; Ying et al., 2005; Zerbini and Libermann, 2005a, b) have been reported in human cancers, including ovarian cancer cells. Furthermore, our recent study also showed that homozygous deletion and downregulation of MKK-4 were detected in ovarian carcinomas (Nakayama et al., 2006a, b) . The above data together with the results reported in this study suggest that cancer cells likely employ at least a dual molecular system to switch off Gadd45-mediated growth suppression and apoptosis, that is, the NF-kB/c-myc/Gadd45 pathway and the NAC-1/Gadd45gip1 pathway. The biological roles of NAC-1 in promoting paclitaxel resistance imply that NAC-1 might be used as a surrogate stand-alone marker or in combination with other markers to predict paclitaxel resistance. Such information may aid in individualized selection of effective therapies in ovarian cancer patients. For example, patients with NAC-1-overexpressing tumors might be treated with chemotherapeutic agents other than paclitaxel in future clinical trials. Furthermore, NAC-1 may also serve as a molecular target to enhance paclitaxel sensitivity in ovarian cancer patients. The results from this study suggest that several strategies can be applied for NAC-1-targeted therapy, including disruption of NAC-1 homodimerization, silencing NAC-1 or forced expression of Gadd45gip1. Although the above represent our favored view, it should be noted that multiple genes and pathways are likely involved in the development of paclitaxel resistance in cancer cells (Duan et al., , 2006a Yusuf et al., 2003; Mabuchi et al., 2004; Materna et al., 2007; Bourguignon et al., 2008) .
In summary, the findings from this study provide a possible molecular mechanism by which NAC-1 overexpression contributes to paclitaxel resistance. Our results show the essential role of NAC-1 homodimerization in conferring paclitaxel resistance and also highlight the critical role of the Gadd45 pathway in mediating this phenotype. It would be of great interest to determine how NAC-1 proteins collaborate with other molecules and pathways in rendering stem cell and drug-resistance phenotypes in cancer cells. Furthermore, as NAC-1 may serve as an upstream transcriptional regulator for several signaling pathways, it would be worthwhile to explore the potential of developing NAC-1-targeted therapy as a means to enhance paclitaxel sensitivity in cancer patients. It might be imagined that NAC-1-targeted therapy could be used either as a stand-alone sensitizing agent for chemotherapeutics, or used in combination with other inhibitors of known drugresistance pathways.
Materials and methods

Cell lines and culture conditions
Cancer cell lines, including 293 T, OVCAR3, SKOV3, A2780 and HeLa cells, were purchased from ATCC (Rockville, MD, USA). All cell lines used in this study were cultured in RPMI1640 medium supplemented with 5% fetal bovine serum. To generate chemoresistant ovarian cancer cells, SKOV3, A2780 and OVCAR3 cells were selected by continuous treatment with different concentrations of paclitaxel (ranging from 0.2 mM-2.0 mM) or carboplatin (0.2 mg/ml-4.0 mg/ ml). Resistant colonies of each cell line were pooled and subsequently used for experiments. Chemoresistant cell lines were maintained in selective medium containing the highest concentrations of paclitaxel (0.25 mM for SKOV3, 0.5 mM for A2780 and OVCAR3) or carboplatin (2.0 mg/ml for SKOV3, 1.0 mg/ml for A2780 and 0.5 mg/ml for OVCAR3) that permitted growth.
Retrovirus, shRNA transfection and generation of N130 mut A retrovirus carrying the Gadd45gip1-V5 expression vector was produced by cloning the entire coding sequence into the pWZL-Hygro retroviral vector. High-titer retroviral stocks were generated using the Phoenix ecotropic packaging cell line. shRNA plasmids that target NAC-1 (pRS-shNAC1) and Gadd45gip1 (pRS-shGadd45gip1), as well as the shRNA plasmid that targets GFP (green fluorescent protein) (pRSshGFP) were obtained from Origene (Rockville, MD, USA). The shRNA plasmids targeting Gadd45g and the control plasmid (pLKO.1-puro vector-only) were obtained from Sigma (St Louis, MO, USA). The shRNA sequences that target different genes are listed in Supplementary Table 1. We have earlier generated N130-inducible cells that express the first 130 amino-acid segment of NAC-1 (N130), which corresponds to the BTB/POZ domain. A mutant of N130, N130 mut , was generated in this study by random mutagenesis using the JBS dNTP-mutagenesis kit (Jena Bioscience, Jena, Germany). To completely abolish the interaction between N130 and NAC-1, we introduced missense mutations that changed 30 amino acids in the N130 fragment. The mutant N130 sequence was then cloned into pcDNA4-Xp and mut tagged with Xpress. Double immunofluorescence was performed as described earlier using V5 and Xpress antibodies (Nakayama et al., 2006a, b) .
Drug sensitivity and cell viability assays For drug sensitivity assays, cells in both experimental and control groups were seeded in 384-well plates at a density of 750 cells/well. After overnight culture, the cells were treated with a series of concentrations of paclitaxel. Four days after transfection (that is, 3 days after drug treatment), viable cell numbers were measured on the basis of the ability of living cells to convert a redox dye (resazurin) into a fluorescent end product (resorufin) using CellTiter-Blue reagent (Promega, Madison, WI, USA). Data read by a fluorescence microplate reader (Fluostar from BMG, Durham, NC, USA) were determined from three replicates, and were expressed as a percent of the group without paclitaxel treatment. IC50 was defined as the concentration that resulted in a 50% decrease in the number of cells, as reflected by fluorescence intensity, compared with that of the control cultures in the absence of the drug.
Quantitative real-time reverse transcription PCR An RNA extraction kit (Qiagen, Germantown, MD, USA) was used to extract total RNA, and the Superscript II First-strand cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA) was used to generate cDNA. Real-time PCR was performed on a Bio-Rad iCyclers (MyIQ, IQ4), and data analysis was performed using the Bio-Rad IQ5 v2 software (Hercules, CA, USA). The PCR primers used in this study are listed in Supplementary Table 1 . The mean Ct of the gene of interest was calculated from replicate measurements and normalized with the mean Ct of a control gene, APP (b-amyloid precursor gene), for which the expression is relatively constant among specimens.
Immunohistochemistry and western blot A mouse monoclonal anti-NAC-1 antibody was obtained from Novus (Littleton, CO, USA) and was used in immunohistochemistry at a dilution of 1:200. The specificity of this antibody has been validated in earlier reports (Nakayama et al., 2006b ). An EnVision þ System peroxidase kit (DAKO, Carpinteria, CA, USA) was used for staining, following the manufacturer's protocol. Immunohistochemical staining was carried out on tissue microarrays containing 113 anonymous high-grade ovarian serous carcinoma tissues for which ex vivo chemoresponse status was available. The definition of extreme drugresistance status was that tumor cell growth was greater than one standard deviation above the median, whereas the low drug resistance was that cell growth was less than the median growth (Holloway et al., 2002; Loizzi et al., 2003) . Immunointensity for NAC-1 was scored using a four-tier system from 0 (undetectable), 1 þ (weakly positive), 2 þ (moderately positive) to 3 þ (intensely positive). This criteria was used in our earlier study (Nakayama et al., 2006b) .
Western blot analysis was conducted using a standard protocol. The antibodies used in this study included a mouse NAC-1 monoclonal antibody at a 1:200 dilution, an anti-V5 antibody (Invitrogen, Cat no. R960-25) at a 1:1000 dilution and a rabbit anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase) polyclonal antibody (Sigma, Cat no. G9545) at a 1:4000 dilution. Similar amounts of total protein from each lysate were loaded and separated on 4-12% Tris-Glycine-SDS polyacrylamide gels (Novex, San Diego, CA, USA) and electroblotted to Millipore Immobilon-P polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). Western blots were developed by chemiluminescence (Pierce, Rockford, IL, USA).
